Xultophy® 100/3.6 (insulin degludec and liraglutide injection) – Expanded indication
February 27, 2019 - The FDA approved Novo Nordisk’s Xultophy 100/3.6 (insulin degludec and liraglutide), as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Download PDF
